Recap: Ultragenyx Pharmaceutical Q4 Earnings
Portfolio Pulse from Benzinga Insights
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported Q4 earnings with an EPS of $-1.52, beating estimates by 6.17% and showing a revenue increase of $24.04 million from the previous year. Despite missing EPS estimates last quarter, the share price increased by 6.09% the following day. The company's past earnings performance shows a pattern of missed EPS estimates but varying revenue figures.
February 15, 2024 | 9:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx Pharmaceutical reported a better-than-expected Q4 EPS of $-1.52, surpassing estimates by 6.17%, with a significant year-over-year revenue increase.
The positive earnings report, particularly the beat on EPS estimates and the significant increase in revenue, is likely to instill investor confidence and could lead to a short-term uptick in RARE's stock price. Historical data shows that even when the company missed EPS estimates in the past, the stock price increased the following day, indicating a positive investor sentiment towards the company's financial health.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100